Clinical trial • Phase III • Other
nolasiban for Healthy volunteers
Phase III trial of nolasiban for Healthy volunteers. 28 participants.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Healthy volunteers
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 18-11-2025
- First CTIS Authorization Date
- 09-01-2026
Trial design
Phase III trial across 1 site in Czechia.
- Target Sample Size
- 28
Recruitment
- Planned Sample Size
- 28
- Recruitment Window Months
- 6
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 28
Czechia
- Earliest CTIS Part Ii Submission Date
- 05-12-2025
- Latest Decision Or Authorization Date
- 09-01-2026
- Processing Time Days
- 35
- Number Of Sites
- 1
- Number Of Participants
- 28
Sites
- Site Name
- Quinta-Analytica s.r.o.
- Department Name
- Clinical Unit
- Contact Person Name
- Jiří Grim
- Contact Person Email
- jiri.grim@quinta.cz
- Number Of Participants
- 28
Sponsor
Primary sponsor
- Full Name
- ReproNovo ApS
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Denmark
Investigational products
- Investigational Product Name
- nolasiban
- Active Substance
- nolasiban
Related trials
Other published trials that may interest you.